U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

			THE UNITED STATES	ATTORNEY'S DOCKET NUMBER PC32107A					
			OFFICE (DO/EO/US) ON UNDER 35 U.S.C. 371	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)					
INTERN		L APPLICATION NO. 2005/000173	INTERNATIONAL FILING DATE January 18, 2005	PRIORITY DATE CLAIMED January 29, 2004					
TITLE O	F INVE	NTION							
1-ISOPROPYL-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE DERIVATIVES HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY									
APPLICANT(S) FOR DO/EO/US									
Tomoki KATO, Kiyoshi KAWAMURA, Chikara UCHIDA									
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:									
1.	\boxtimes	This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.							
2.		This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.							
3.	\boxtimes	This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.							
4.	\boxtimes	The US has been elec	ted (Article 31).						
5.	\boxtimes								
	A copy o	of the International Applic	cation as filed (35 U.S.C. 371(c)(2))						
	a.	is attached l	nereto (required only if not communic	ated by the International Bureau).					
	b.	has been communicated by the International Bureau.							
	C.	is not required, as the application was filed in the United States Receiving Office (RO/US).							
6.		An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).							
	a.	is attached hereto.							
	b.	has been previously submitted under 35 U.S.C. 154(d)(4).							
7.	\boxtimes	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).							
	a.	are attached hereto (required only if not communicated by the International Bureau).							
	b.	have been c	communicated by the International Bu	reau.					
	C.	have not been made; however, the time limit for making such amendments has NOT expired.							
	d.	have not been made and will not be made.							
8.		An English language t	ranslation of the amendments to the	claims under PCT Article 19 (35 U.S.C. 371(c)(3)).					
9.	$\overline{\boxtimes}$	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).							
10.		An English language translation of the annexes of the International Preliminary Examination Report under PCT Article							
36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included:									
11.	П			nd 1.98					
12.	H	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.							
13		An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.							
		A preliminary amendment.							
14		An Application Data Sheet under 37 CFR 1.76.							
15.	\boxtimes	A substitute specification. 16. A power of attorney and/or change of address letter.							
16.		A power of attorney and/or change of address letter							
17.	\vdash	A computer-readable form of the sequence listing in accordance with PCT Rule 13fer.2 and 37 CFR 1.821- 1.825.							
18.		A second copy of the published International Application under 35 U.S.C. 154(d)(4).							
19.		A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).							

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Form PTO-1390 (Rev. 07-2005)

U.S. APPLICATION	N NO. (if known see 37 CFR	INTERNATIONAL FILING DATE January 18, 2005		On unless it displays a valid OMB control number TORNEY'S DOCKET NUMBER PC32107A			
20. Other items or information:							
The Following Fee	s have been submitted				CALCULATIONS	PTO USE ONLY	
l 🛁	\$300	\$ 300.00					
22. Examination fee (37 CFR 1.492(c)) If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provision of PCT Article 33(1)-(4)							
23. If the written opinio by IPEA/ Search fee (37 CFI International Search previous) All other situations	\$ 400.00						
Total of 21, 22 and 23 =							
Additional sequence The fee i	uding						
Total Sheets	Extra Sheets		per of each additional 50 or fraction of (round up to a whole number)	RATE	\$		
50 -100 =	/50=			x \$250	0		
Surcharge of \$130.00 for furnishing any of the search fee, examination fee, or the oath or declaration after the date of commencement of the national state (37CFR 1.492(h)).							
CLAIMS	NUMBER FILED		NUMBER EXTRA	RATE	\$		
Total claim	s 15 -20=	0		x \$50	\$0		
Independent claims	s 1-3=	0		x \$200	\$0		
MULTIPLE DEPEN	IDENT CLAIM(S) (if applicat	ble)		+ \$360	\$0		
	LCULATIONS =	\$900					
Applican	Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by 1/2						
	\$900						
Processing fee of \$130 for furnishing the English translation later than 30 months from the earliest claimed priority date(37 CFR 1.492(i)).							
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +							
TOTAL FEES ENCLOSED =							
					Amount to be refunded:	\$	
					Amount to be charged	\$ 900.00	

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

a.		A check in the amount of \$ to cov	ver the above fees ins enclosed.			
b.	\boxtimes	Please charge my Deposit Account No. <u>16-1445</u> in the amount of \$ <u>900</u> to cover the above fees				
		A duplicate copy of this sheet is enclosed.				
C.	\boxtimes	The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>16-1445</u> . A duplicate copy of this sheet is enclosed.				
d.		Fees are to be charged to a credit card. WARNING : Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.				
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.						
SEND ALL CORRESPONDENCE TO:						
Gregg C. Benson						
Pfizer Inc. Eastern Point Road, MS 8260-1611						
	, CT 063	•	/ Frank W Forman /			
	•		SIGNATURE			
			Frank W. Forman			
			NAME			
			IVANE			
			42,547			
			REGISTRATION NUMBER			